Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents

Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents

Hepatitis C virus (HCV) genotype 3 is responsible for 30.1% of chronic hepatitis C infection cases worldwide. In the era of direct-acting antivirals, these patients have become one of the most challenging to treat, due to fewer effective drug options, higher risk of developing cirrhosis and hepatoce...

Full description

Bibliographic Details
Main Authors:	L.P. Zanaga, N. Miotto, L.C. Mendes, R.S.B. Stucchi, A.G. Vigani
Format:	Article
Language:	English
Published:	Associação Brasileira de Divulgação Científica
Series:	Brazilian Journal of Medical and Biological Research
Subjects:	Hepatitis C treatment Genotype 3 Sofosbuvir Daclatasvir Ribavirin
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2016001100302&lng=en&tlng=en

Similar Items

Recurrent hepatitis C treatment with direct acting antivirals – a real life study at a Brazilian liver transplant center
by: L.P. Zanaga, et al.

Sofosbuvir-Based Therapies Achieved Satisfactory Virological Response in Chinese Individuals with Genotypes 3 and 6 Infections: A Real-World Experience
by: Tang Q, et al.
Published: (2021-06-01)

Efficacy decrease of antiviral agents when administered to ongoing hepatitis C virus infections in cell culture
by: Carlos García-Crespo, et al.
Published: (2022-08-01)

Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries
by: Melissa J. Barber, et al.
Published: (2020-09-01)

EFFICACY AND BENEFICIAL EFFECTS OF SOFOSBUVIR WITH DACLATASVIR ON LIVER FUNCTIONS OF EARLIER TREATMENT FAILURE PATIENTS INFECTED WITH GENOTYPE 3 OF HEPATITIS C VIRUS
by: Sumetha Yaseen, et al.
Published: (2020-04-01)

Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- a prospective interventional clinical trial
by: Shafiq Ur Rehman Cheema, et al.
Published: (2019-11-01)

The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C
by: Irina RUSU, et al.
Published: (2020-03-01)

High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C
by: Andrew Hill, et al.
Published: (2017-10-01)

Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?
by: Jong Eun Yeon
Published: (2018-09-01)

Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
by: Andrew Hill, et al.
Published: (2018-04-01)

Effectiveness and Safety of Sofosbuvir-Velpatasvir in Patients with Cirrhosis Associated with Genotype 3 Hepatitis C Infection in Xinjiang, China
by: Abulitifu Y, et al.
Published: (2022-11-01)

Real-life results of sofosbuvir based therapy for patients with hepatitis C
by: D. G. Zhivitsa, et al.
Published: (2019-09-01)

Validated Reversed-Phase Liquid Chromatographic Method with Gradient Elution for Simultaneous Determination of the Antiviral Agents: Sofosbuvir, Ledipasvir, Daclatasvir, and Simeprevir in Their Dosage Forms
by: Essam Ezzeldin, et al.
Published: (2020-10-01)

Safety and efficacy of directly acting antivirals (sofosbuvir and daclatasvir) in treatment of chronic HCV in HIV-HCV co-infected Egyptian patients
by: Inas E L-Khedr Mohamed, et al.
Published: (2021-04-01)

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
by: Phil McEwan, et al.
Published: (2017-07-01)

Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil
by: Iandra Holzmann, et al.

Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study
by: Barnaby Flower, et al.
Published: (2023-01-01)

Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study
by: Phunchai Charatcharoenwitthaya, et al.
Published: (2020-03-01)

Efficacy of daclatasvir plus peginterferon alfa and ribavirin for patients with chronic hepatitis C genotype 4 infection
by: Hussien Ahmed, et al.
Published: (2017-03-01)

Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection
by: Ahmed OA, et al.
Published: (2018-03-01)

Prescription and efficacy of daclatasvir and sofosbuvir ± ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries: The CMPASS-EU cohort study
by: Stefan Bourgeois, et al.
Published: (2020-01-01)

Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders
by: Heidar Sharafi, et al.
Published: (2021-10-01)

Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study
by: Young Min Kim, et al.
Published: (2018-09-01)

The Efficacy of Generic Daclatasvir-Sofosbuvir as Pan-Genotypic Regiment for Hepatitis C Virus (HCV) Infected Patients in Bandung Indonesia
by: Muhammad Begawan Bestari, et al.
Published: (2020-07-01)

Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin
by: Tatsuo Kanda, et al.
Published: (2017-05-01)

The efficacy and safety of direct-acting antiviral drugs in the management of hepatitis C virus-related arthritis
by: Samah M. Alian, et al.
Published: (2020-09-01)

<i>Interleukin 28B</i> Polymorphism as a Predictor of Sustained Virological Response to Sofosbuvir-Based Therapy for Hepatitis C Virus Patients
by: Seham Mahrous Zaki, et al.
Published: (2022-09-01)

Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan
by: Saima Mushtaq, et al.
Published: (2020-09-01)

Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life
by: Pol S, et al.
Published: (2016-03-01)

Circulating microRNAs as predictors of response to sofosbuvir + daclatasvir + ribavirin in in HCV genotype-4 Egyptian patients
by: Noha Anwar Hassuna, et al.
Published: (2022-12-01)

Safety and Efficacy of Sofosbuvir and Daclatasvir in The Treatment of Chronic HCV Infection in Elderly Egyptian Patients
by: Mohamed G. Mohamed, et al.
Published: (2021-01-01)

The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir
by: Walker DR, et al.
Published: (2015-12-01)

Treatment of viral hepatitis C genotypes 1 and 2 by sofosbuvir and ledipasvir with or without ribavirin combination: A possible alternative to pangenotypic treatment in a low-income country?
by: Chantelli Iamblaudiot Razafindrazoto, et al.
Published: (2021-06-01)

Treatment efficacy and tolerability of Sofosbuvir and Ribavirin for chronic hepatitis C infection in post renal transplant patients – A retrospective single centre study
by: B Kirushnan, et al.
Published: (2016-01-01)

Detection of a genetic footprint of the sofosbuvir resistance-associated substitution S282T after HCV treatment failure
by: Andreas Walker, et al.
Published: (2017-06-01)

Serum MicroRNA profiles in chronic hepatitis C Egyptian patients before and after combined sofosbuvir and daclatasvir treatment
by: Wafaa M. Ezzat, et al.
Published: (2024-01-01)

Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis
by: Sperl J, et al.
Published: (2017-06-01)

Assessing the impact of a combination of sofosbuvir and daclatasvir treatment for hepatitis C virus infection on heart rate, rhythm and heart rate variability using 24-hour ECG monitoring
by: Ahmed Mohamed El Missiri, et al.
Published: (2020-07-01)

Association of multiple mutations in NS5A and NS5B genes and resistance to direct-acting antivirals in chronically infected Egyptian patients with Hepatitis C virus Genotype 4a
by: Gehad M. Mohamed, et al.
Published: (2024-02-01)

Incidence of retinopathy in patients with chronic hepatitis C treated with dual and triple antiviral protocols
by: Mouaz A Abd-Elhadi, et al.
Published: (2019-01-01)